SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls N Le Bert, AT Tan, K Kunasegaran, CYL Tham, M Hafezi, A Chia, ... Nature 584 (7821), 457-462, 2020 | 2045 | 2020 |
Dengue prevention and 35 years of vector control in Singapore EE Ooi, KT Goh, DJ Gubler Emerging infectious diseases 12 (6), 887, 2006 | 693 | 2006 |
Dengue A Wilder-Smith, EE Ooi, O Horstick, B Wills The Lancet 393 (10169), 350-363, 2019 | 564 | 2019 |
Etiology of severe non-malaria febrile illness in Northern Tanzania: a prospective cohort study JA Crump, AB Morrissey, WL Nicholson, RF Massung, RA Stoddard, ... PLoS neglected tropical diseases 7 (7), e2324, 2013 | 465 | 2013 |
Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness G Manokaran, E Finol, C Wang, J Gunaratne, J Bahl, EZ Ong, HC Tan, ... Science 350 (6257), 217-221, 2015 | 414 | 2015 |
IL-1β, IL-6, and RANTES as biomarkers of Chikungunya severity LFP Ng, A Chow, YJ Sun, DJC Kwek, PL Lim, F Dimatatac, LC Ng, EE Ooi, ... PloS one 4 (1), e4261, 2009 | 369 | 2009 |
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs ELC Tan, EE Ooi, CY Lin, HC Tan, AE Ling, B Lim, LW Stanton Emerging infectious diseases 10 (4), 581, 2004 | 332 | 2004 |
Seroepidemiology of human enterovirus 71, Singapore EE Ooi, MC Phoon, B Ishak, SH Chan Emerging infectious diseases 8 (9), 995, 2002 | 310 | 2002 |
Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness L Tanner, M Schreiber, JGH Low, A Ong, T Tolfvenstam, YL Lai, LC Ng, ... PLoS neglected tropical diseases 2 (3), e196, 2008 | 309 | 2008 |
A dynamic immune response shapes COVID-19 progression EZ Ong, YFZ Chan, WY Leong, NMY Lee, S Kalimuddin, SMH Mohideen, ... Cell host & microbe 27 (6), 879-882. e2, 2020 | 306 | 2020 |
Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries J Barniol, R Gaczkowski, EV Barbato, RV da Cunha, D Salgado, ... BMC infectious diseases 11, 1-12, 2011 | 298 | 2011 |
Naturally acquired human Plasmodium knowlesi infection, Singapore OT Ng, EE Ooi, CC Lee, PJ Lee, LC Ng, SW Pei, TM Tu, JP Loh, YS Leo Emerging infectious diseases 14 (5), 814, 2008 | 284 | 2008 |
Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention EE Ooi, DJ Gubler Cadernos de saude publica 25, S115-S124, 2009 | 278 | 2009 |
Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development A Wilder-Smith, EE Ooi, SG Vasudevan, DJ Gubler Current infectious disease reports 12, 157-164, 2010 | 270 | 2010 |
The structural basis for serotype-specific neutralization of dengue virus by a human antibody EP Teoh, P Kukkaro, EW Teo, APC Lim, TT Tan, A Yip, W Schul, M Aung, ... Science translational medicine 4 (139), 139ra83-139ra83, 2012 | 251 | 2012 |
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial NI Paton, L Lee, Y Xu, EE Ooi, YB Cheung, S Archuleta, G Wong, ... The Lancet infectious diseases 11 (9), 677-683, 2011 | 247 | 2011 |
Horstick, & Wills, B.(2019) A Wilder-Smith, EE Ooi Dengue. The Lance 393 (10169), 350-363, 0 | 234 | |
Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial JG Low, C Sung, L Wijaya, Y Wei, APS Rathore, S Watanabe, BH Tan, ... The Lancet infectious diseases 14 (8), 706-715, 2014 | 233 | 2014 |
Current status of dengue therapeutics research and development JGH Low, EE Ooi, SG Vasudevan The Journal of infectious diseases 215 (suppl_2), S96-S102, 2017 | 221 | 2017 |
Diagnosis of dengue: an update KF Tang, EE Ooi Expert review of anti-infective therapy 10 (8), 895-907, 2012 | 217 | 2012 |